Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.69 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.69 |
| ▸ | CHKA | P35790 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL22412976 | 0.98 | CHKA (0.70) | F2PRSS1CHKAALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL19468767 | 0.98 | F2 (0.67) | F2PRSS1CHKAALDH1A1LMNA | |
| SCHEMBL13283227 | 0.83 | CHKA (0.61) | F2PRSS1CHKAALDH1A1LMNA | |
| SCHEMBL18459220 | 0.82 | CHKA (0.61) | F2PRSS1CHKAALDH1A1LMNA | |
| Benzyl Viologen SCHEMBL1108041 | 0.81 | ALDH1A1 (0.74) | F2PRSS1CHKAALDH1A1LMNA | |
| SCHEMBL93665 | 0.80 | CHKA (0.59) | F2PRSS1CHKAALDH1A1LMNA | |
| SCHEMBL19504329 | 0.80 | MAOB (0.58) | F2PRSS1CHKAALDH1A1LMNA | |
| Bromide SCHEMBL7322480 | 0.79 | F2 (0.72) | F2PRSS1CHKASMN1; SMN2RAB9A | |
| SCHEMBL10326023 | 0.79 | CHKA (0.61) | F2PRSS1CHKAALDH1A1LMNA | |
| Benzyl Viologen SCHEMBL1930045 | 0.79 | ALDH1A1 (0.78) | CHKAALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185812-A1 | INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS | THE ROCKEFELLER UNIVERSITY (US) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185812-A1 | INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS | CGAS, STING1, IRF3 | F2 4793/4885PRSS1 1406/4885CHKA 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.